Cohance Lifesciences reports ₹45.19 crore loss in Q1 on lower revenue
Cohance Lifesciences reported a net loss of ₹45.19 crore for the first quarter, citing lower revenue and shipment phasing in its CDMO business. The company also disclosed receiving five observations from the U.S. FDA following an inspection of its Hyderabad facility.
Why it matters
Financial performance and regulatory compliance are key indicators for investors in the pharmaceutical manufacturing sector.
Contract development and manufacturing organisation (CDMO) Cohance Lifesciences (formerly Suven Pharmaceuticals) reported ₹45.19 crore loss on a consolidated basis for the quarter ended June compared to the ₹46.40 crore net profit in the year earlier period.
Total income declined to ₹434.51 crore (₹563.48 crore), which the company attributed to shipment phasing in pharma CDMO, a softer contribution from agrochemicals, lower formulations revenue and timing of execution across parts of the portfolio.. A strong growth at subsidiary Sapala and resilient API (Active Pharmaceutical Ingredient) performance helped.
Gross margins contracted to 71.5% from 73.0% in Q1FY26, largely due to product mix and a lower contribution from the CDMO business at 38%, reflecting the lumpy nature of the business and phasing of orders towards the second half (H2), the company said.
For the quarter ended March, the company had reported ₹8.31 crore net profit on ₹617.28 crore total income.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in